Introduction
Atrial fibrillation (AF) is an expanding epidemic, 1 and ischaemic stroke due to cardioembolism remains a trademark serious complication of AF. 2 The now historical stroke prevention in AF trials demonstrated that compared with placebo/control, anticoagulation with a vitamin K antagonist (VKA, e.g. warfarin) reduced stroke by 64% while also reducing all-cause mortality in patients with non-valvular AF, whereas platelet inhibition with aspirin had a non-significant 19% reduction in stroke and no benefit on mortality. 3 Thus, effective stroke prevention means oral anticoagulation. Although highly effective, antithrombotic drugs increase the risk of bleeding events, and the expected benefits and harms for the individual patient must be carefully weighed when deciding on whether or not to initiate treatment. More specifically, a certain absolute level of thromboembolic risk is required before the protective antithrombotic effect outweighs the associated serious bleeding risk. To alleviate this clinical conundrum and aid decision making, the use of validated stroke and bleeding risk scores is recommended. 4 The treatment threshold debate Most contemporary guidelines recommend using the CHA 2 DS 2 -VASc score to determine whether an atrial fibrillation (AF) patient has an indication for antithrombotic treatment. [5] [6] [7] [8] Nonetheless, guideline recommendations are conflicting (see Table 1 ). Some guidelines have used the CHA 2 DS 2 -VASc score in a categorical manner, artificially dividing patients into low-, moderate-and, high-risk strata-and making treatment recommendations based on these strata. Also, all guidelines actually provide treatment recommendations that extend beyond what has been specifically investigated in randomized trials.
Randomized trials are the gold standard to testing the effectiveness and safety of an intervention but clinical trials focus on highly selected populations with specific inclusion/exclusion criteria. The historical stroke prevention trials testing the effect of antithrombotic therapy against no treatment or antiplatelet therapy have only investigated the overall effect in populations dominated by patients with multiple stroke risk factors, and there are no randomized trials investigating the risk of stroke and bleeding of antithrombotic drugs vs. placebo according to specific CHA 2 DS 2 -VASc scores, particularly so for those with lower scores. Thus, guideline recommendations instead have to rely on observational studies of untreated populations that report on rates of thromboembolism across the range of CHA 2 DS 2 -VASc scores.
In a modelling analysis, it has been estimated that a population with an ischaemic stroke rate above 1.7 per 100-person years will benefit from treatment with a vitamin K antagonist (VKA), while treatment with dabigatran, a non-VKA oral anticoagulant, lowers this treatment threshold to 0.9 events per 100-person years, mainly due to a lower risk of intracranial bleeding. 9 Even the 1.7 per 100 person-years threshold for the VKAs could be lower, if there was better quality of anticoagulation control, as reflected by an average time in therapeutic range >70%.
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If we can consistently identify patient populations with stroke rates below and above these recommended treatment thresholds, choosing candidates for anticoagulation would be a relatively simple task. 2.4 , while in patients with a score of 1 the reported rates ranged from 0.10 to 6.6. 11,12 In addition, stroke rates also vary depending on which risk factor contributes to the score of 1. 13,14 In other words, depending on the population studied, stroke rates in patients with CHA 2 DS 2 -VASc scores of both 0 and 1 may therefore reside either below or above the suggested treatment thresholds. The wide variations in stroke rates have only added fuel to the unfinished debate about which CHA 2 DS 2 -VASc score level should trigger an indication for anticoagulation. [14] [15] [16] [17] [18] Stroke rates based on analyses of nationwide Danish administrative hospital registries have played an important role in the formulation of contemporary guidelines. 5, 19, 20 The magnitude of these event rates has been questioned by reports from a comparable Swedish registry, which reported ischaemic stroke rates among AF patients with low CHA 2 DS 2 -VASc scores to be much lower than Danish rates, and also well below the suggesting treatment thresholds for assumed benefit from treatment.
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How do we explain the observed variation in stroke rates? Importantly, using event rates as a way of quantifying absolute risk is challenged by several factors, some of which can be controlled such as the study design, and some due to circumstances that are more difficult or impossible to control, e.g. information issues such as misclassification of both exposure and outcome, or selection bias due to informative censoring. 22, 23 Potential modifying factors are summarized in Table 2 , as discussed further below.
Variations in reported stroke rates
When aiming to estimate stroke risk in a non-anticoagulated AF population, an issue that requires careful consideration is how to handle anticoagulant treatment initiated after recruitment of the participants.
Obviously, baseline users of anticoagulation should be excluded, but what about patients who initiate treatment during follow-up?
In the key literature quantifying stroke rates in AF this has been dealt with in various ways. One approach has been to ignore that some patients initiate treatment during follow-up. 19, 20 This is likely to yield conservative stroke rates, since such an analysis would also include person-time on anticoagulation, which effectively lowers stroke risk. 3 An alternative approach has been to exclude -at baseline-all patients who initiate anticoagulation during follow-up, which introduces 'conditioning on the future'. This may bias the reported event rates downwards given that the high(er)-risk patients initiated on anticoagulation during follow-up are excluded. 15, 21 Such an approach may also underestimate stroke risk because the baseline exclusion criterion, initiating anticoagulant treatment, is likely to identify patients who recently survived a thromboembolic event. Hence, the remarkably low stroke rates from Swedish registries, which have questioned current European guideline recommendations, may be explained in part by this inappropriate methodology. 15, 21 Indeed, a recent analysis of the Danish nationwide registry data demonstrated that this baseline exclusion of patients based on future events yielded lower stroke rates than a more appropriate approach with right censoring at time of initiation of anticoagulant treatment, especially for patients in the lower spectrum of the CHA 2 DS 2 -VASc score. 24 Importantly, the right censoring approach allows for inclusion of stroke events prior to initiation of treatment, while at the same time avoiding the inclusion of person-time on anticoagulation. This right-censoring approach has also previously been used to estimate stroke rates in an untreated AF population. 25, 26 As depicted in Table 2 , other factors than study design choices contribute to the challenge of using administrative hospital discharge databases to reliably estimating stroke risk according to specific CHA 2 DS 2 -VASc score levels. Some factors underestimate rates while others contribute to overestimation, and the sum of distortion caused by these modifying forces is not easily predictable. The exact magnitude of reported event rates for a particular score point should therefore not (regardless of study design) be attributed too much weight in the formulation of guideline recommendations. 
'Real world' comparative effectiveness
Randomized trials are the gold standard for answering questions about drug effects, but such trials are unlikely to be performed for patients with lower CHA 2 DS 2 -VASc scores contrasting oral anticoagulant treatment vs. no treatment. In attempts to emulate such a trial, a few observational studies have investigated the net clinical benefit (NCB) of anticoagulation vs. aspirin vs. no treatment in men and women with CHA 2 DS 2 -VASc scores of 1 and 2, respectively, corresponding to the current European guideline treatment threshold category. Unanimously, they report a positive NCB for anticoagulation also in this population, with anticoagulation also being superior to both aspirin and no treatment. [27] [28] [29] Limitations pertaining to these studies also deserve mention. Some patients may have had their risk score level underestimated since the register-based ascertainment of comorbidities may lack sensitivity for some score components, e.g. hypertension, diabetes mellitus, and vascular disease. Risk score underestimation may be more frequent among patients who initiated anticoagulation (given that a higher score is a clear indication for anticoagulation) and this could inflate the effect of anticoagulation relative to aspirin or no treatment, given that higher risk score level also equates to higher ischaemic risk. Confounding by indication, for example, by lower bleeding risk or greater disease severity in those started on anticoagulation, is another key concern in observational comparative effectiveness studies that potentially could explain the observed benefit of anticoagulation. 30 Despite careful adjustment for important confounding factors including bleeding risk in some of the available studies, 27, 28 confounding may remain an intractable threat to the internal validity.
Whether misclassification of the risk score level and confounding by indication fully explains the observed superiority of anticoagulation is uncertain but the available observational NCB should be interpreted with this in mind. Also, NCB can be defined in many different ways and varying weights have been applied to the NCB risk factor components. 31, 32 Nonetheless, the available studies investigating the NCB according to the European threshold category (CHA 2 DS 2 -VASc 1 in men and 2 in women) all do indicate that oral anticoagulation is associated with a positive NCB while also being preferred over aspirin or no treatment.
Let's talk about sex
Female sex is attributed 1 point on the CHA 2 DS 2 -VASc score. This is based on several observations of an overall higher risk of stroke following a diagnosis of AF in women vs. men, although many of the initial studies have focused on older populations or those having 1 stroke risk factors. 33 However, there is an age dependency to the relation between female sex and stroke rates. When stratified by age, women younger than 65 years have similar or even lower stroke rates than age-comparable men, [34] [35] [36] and women with a score of 1 alone have rates that are likely to be too low to merit anticoagulation. 26 Based on this age/sex interaction, European guidelines raised their threshold for oral anticoagulation for women from CHA 2 DS 2 -VASc 1 in 2010 to CHA 2 DS 2 -VASc 2 in the 2012 edition update, essentially stating that sex should not inform treatment decisions as long as the current age threshold applies. 5, 37 In keeping with this approach, current Canadian guidelines also provide treatment recommendations that are similar for men and women, 7 while contemporary American guidelines have ignored these important observations and still provide the possibility of initiating anticoagulation based on female sex alone. 6 
Conclusion
In conclusion, in the absence of randomized trials investigating the benefit of anticoagulation in patients at the lower end of the CHA 2 DS 2 -VASc risk spectrum, observational studies retain an important role in defining the most appropriate treatment threshold. 38 There are currently no data supporting that women with no additional risk factor on the CHA 2 DS 2 -VASc score will benefit from antithrombotic treatment. Thus, we are closing in on the treatment threshold for stroke prevention in AF as offered by CHA 2 DS 2 -VASc, and current European guidelines likely define how low we can go.
Notwithstanding the inherent limitations of observational studies to answer questions about drug effects, the existing body of evidence suggests that anticoagulation administered as defined by the European guideline treatment threshold (CHA 2 DS 2 -VASc 1 for men and 2 for women) is associated with a NCB that is superior to both aspirin and no treatment. However, current guideline discrepancies also reflect the fact that the level of stroke risk among men with a score of 1 and women with a score of 2 is on the borderline of where the impact of anticoagulation treatment shifts from beneficial to harmful. When doubt persists, the presence of one or more non-CHA 2 DS 2 -VASc stroke risk factors could further strengthen the decision to offer anticoagulation. 39, 40 An individualized decision with careful weighing of patient values and preferences, 41, 42 along with the expected benefits and harms of anticoagulation is therefore necessary.
